Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies
The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD). These were 12-week, double-blind, placebo-controlled, para...
Saved in:
| Published in | Respiratory medicine Vol. 109; no. 9; pp. 1155 - 1163 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.09.2015
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0954-6111 1532-3064 1532-3064 |
| DOI | 10.1016/j.rmed.2015.06.006 |
Cover
| Abstract | The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD).
These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85; the secondary endpoint was 0–6 h post-dose weighted mean (WM) FEV1 at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed.
In both studies, trough FEV1 was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111–0.128 L, all p < 0.001 [Day 85]), as was 0–6 h post-dose WM FEV1 (range: 0.135–0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: −2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30–39%), as were cardiovascular AEs of special interest (<1–3%) and pneumonia AEs (0–1%).
Overall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent.
The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option.
•Umeclidinium (UMEC) is a long-acting muscarinic antagonist indicated for the treatment of COPD.•Fluticasone furoate/vilanterol (FF/VI) is a corticosteroid/long acting beta agonist for COPD.•These data show that triple therapy with UMEC + FF/VI significantly improves lung function vs FF/VI.•Safety profiles were consistent across all treatment groups in both studies. |
|---|---|
| AbstractList | The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD).
These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85; the secondary endpoint was 0–6 h post-dose weighted mean (WM) FEV1 at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed.
In both studies, trough FEV1 was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111–0.128 L, all p < 0.001 [Day 85]), as was 0–6 h post-dose WM FEV1 (range: 0.135–0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: −2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30–39%), as were cardiovascular AEs of special interest (<1–3%) and pneumonia AEs (0–1%).
Overall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent.
The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option.
•Umeclidinium (UMEC) is a long-acting muscarinic antagonist indicated for the treatment of COPD.•Fluticasone furoate/vilanterol (FF/VI) is a corticosteroid/long acting beta agonist for COPD.•These data show that triple therapy with UMEC + FF/VI significantly improves lung function vs FF/VI.•Safety profiles were consistent across all treatment groups in both studies. The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD). These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85; the secondary endpoint was 0-6 h post-dose weighted mean (WM) FEV1 at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed. In both studies, trough FEV1 was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111-0.128 L, all p < 0.001 [Day 85]), as was 0-6 h post-dose WM FEV1 (range: 0.135-0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: -2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30-39%), as were cardiovascular AEs of special interest (<1-3%) and pneumonia AEs (0-1%). Overall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent. The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option. The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD).OBJECTIVEThe aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD).These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85; the secondary endpoint was 0-6 h post-dose weighted mean (WM) FEV1 at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed.METHODSThese were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85; the secondary endpoint was 0-6 h post-dose weighted mean (WM) FEV1 at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed.In both studies, trough FEV1 was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111-0.128 L, all p < 0.001 [Day 85]), as was 0-6 h post-dose WM FEV1 (range: 0.135-0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: -2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30-39%), as were cardiovascular AEs of special interest (<1-3%) and pneumonia AEs (0-1%).RESULTSIn both studies, trough FEV1 was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111-0.128 L, all p < 0.001 [Day 85]), as was 0-6 h post-dose WM FEV1 (range: 0.135-0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: -2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30-39%), as were cardiovascular AEs of special interest (<1-3%) and pneumonia AEs (0-1%).Overall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent.CONCLUSIONOverall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent.The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option.CLINICAL RELEVANCEThe results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option. Abstract Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD). Methods These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1 ) on Day 85; the secondary endpoint was 0–6 h post-dose weighted mean (WM) FEV1 at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed. Results In both studies, trough FEV1 was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111–0.128 L, all p < 0.001 [Day 85]), as was 0–6 h post-dose WM FEV1 (range: 0.135–0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: −2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30–39%), as were cardiovascular AEs of special interest (<1–3%) and pneumonia AEs (0–1%). Conclusion Overall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent. Clinical relevance The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option. Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD). Methods These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 μg; N = 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85; the secondary endpoint was 0-6 h post-dose weighted mean (WM) FEV1at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ). Adverse events (AEs) were also assessed. Results In both studies, trough FEV1was significantly improved with UMEC + FF/VI (62.5 μg and 125 μg) versus PBO + FF/VI (range: 0.111-0.128 L, all p < 0.001 [Day 85]), as was 0-6 h post-dose WM FEV1(range: 0.135-0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically significant improvements with UMEC + FF/VI versus PBO + FF/VI in one study only and with UMEC 62.5 μg only (difference in SGRQ total score from baseline between treatments: -2.16, p < 0.05). Across all treatment groups, the overall incidences of AEs were similar (30-39%), as were cardiovascular AEs of special interest (<1-3%) and pneumonia AEs (0-1%). Conclusion Overall, the addition of UMEC to FF/VI therapy resulted in significant improvements in lung function compared with PBO + FF/VI in patients with COPD, with similar safety profiles, though SGRQ results were inconsistent. Clinical relevance The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option. |
| Author | Ali, Rehan Donald, Alison Siler, Thomas M. Church, Alison Kerwin, Edward Sousa, Ana R. |
| Author_xml | – sequence: 1 givenname: Thomas M. surname: Siler fullname: Siler, Thomas M. email: thomas.siler.md@midwestchest.com organization: Midwest Chest Consultants, PC, 330 First Capitol Drive, Suite 470, St Charles, MO, USA – sequence: 2 givenname: Edward surname: Kerwin fullname: Kerwin, Edward organization: Clinical Research Institute of Southern Oregon, Medford, OR, USA – sequence: 3 givenname: Ana R. surname: Sousa fullname: Sousa, Ana R. organization: GSK, Respiratory Medicines Development Centre, Stockley Park, Middlesex, UK – sequence: 4 givenname: Alison surname: Donald fullname: Donald, Alison organization: GSK, Respiratory and Immuno-Inflammation, Research Triangle Park, NC, USA – sequence: 5 givenname: Rehan surname: Ali fullname: Ali, Rehan organization: GSK, Respiratory Medicines Development Centre, Stockley Park, Middlesex, UK – sequence: 6 givenname: Alison surname: Church fullname: Church, Alison organization: GSK, Respiratory and Immuno-Inflammation, Research Triangle Park, NC, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26117292$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1rFDEUHaRit9U_4IMEfPFltzeZmcxOkYKU-gEFwY_nkEluMOtMsuZjZf0j_l0zbIuwYH0KhHPuufecc1adOO-wqp5TWFGg_GKzChPqFQParoCvAPijakHbmi1r4M1JtYC-bZacUnpancW4AYC-aeBJdcrKZ8d6tqh-3xhjlVR7Ip0mURpMe-INyROq0WrrbJ6I1Bo1SZ6YMaeCjmUPYnLwMuHFzo7SJQx-JNYR9S14ZxXxQ0whq2R3SLZ5nLyTYU-0jSgjXpJPGPOY4qyUfnoSirif7K-iElPWFuPT6rGRY8Rnd-959fXtzZfr98vbj-8-XL-5XSoOTVp2daf5mgOtueaDlMNgDCqQpmb90EqJ647rZmBKgWZmUA1w1dSd6uuBMt7K-rx6dZi7Df5HxpjEZKPCsdyEPkdBOwq8Zeu-LtCXR9CNz8GV7QoKetYAq_uCenGHykNJR2yDncrp4t7yAlgfACr4GAMaoWySyXqXgrSjoCDmdMVGzOmKOV0BXJR0C5UdUe-nP0h6fSBhsXFnMYioLDqF2gZUSWhvH6ZfHdFLL0rCcvyOe4x_LRCRCRCf587NlSs9nPs223b57wH_U_8Da1fpvw |
| CitedBy_id | crossref_primary_10_1016_j_chest_2018_12_016 crossref_primary_10_1007_s40267_018_0513_3 crossref_primary_10_21518_2079_701X_2018_15_28_37 crossref_primary_10_1080_14656566_2019_1570133 crossref_primary_10_1007_s41030_016_0012_4 crossref_primary_10_1136_bmj_k4388 crossref_primary_10_1136_dtb_2018_4_0611 crossref_primary_10_1183_23120541_00061_2019 crossref_primary_10_1093_qjmed_hcv212 crossref_primary_10_1183_13993003_02208_2022 crossref_primary_10_1164_rccm_201704_0760ED crossref_primary_10_1038_npjpcrm_2016_31 crossref_primary_10_1007_s40265_015_0532_5 crossref_primary_10_2147_COPD_S302864 crossref_primary_10_1080_15412555_2018_1481022 crossref_primary_10_1183_13993003_00302_2022 crossref_primary_10_1016_j_rmed_2016_03_018 crossref_primary_10_1038_s41598_022_18353_y crossref_primary_10_1016_j_rmed_2018_10_024 crossref_primary_10_1111_crj_13026 crossref_primary_10_1177_17534666231155778 crossref_primary_10_1080_17476348_2016_1184976 crossref_primary_10_1007_s12325_020_01311_3 crossref_primary_10_18093_0869_0189_2019_29_2_199_206 crossref_primary_10_4187_respcare_06174 crossref_primary_10_1016_j_aprim_2018_02_007 crossref_primary_10_1016_j_rmed_2018_04_014 crossref_primary_10_1186_s12931_024_02672_x crossref_primary_10_1159_000512064 crossref_primary_10_1186_s12962_018_0101_3 crossref_primary_10_1183_13993003_02165_2015 crossref_primary_10_1007_s12325_018_0771_4 crossref_primary_10_1007_s40265_017_0713_5 crossref_primary_10_1080_17512433_2022_2071700 crossref_primary_10_1177_1753466618760779 crossref_primary_10_18093_0869_0189_2020_30_6_813_821 crossref_primary_10_1002_14651858_CD011897_pub2 crossref_primary_10_1016_S0140_6736_16_31354_X crossref_primary_10_1080_17476348_2018_1548936 crossref_primary_10_2174_1573398X15666190314151921 crossref_primary_10_21518_2079_701X_2021_16_10_16 crossref_primary_10_1056_NEJMoa1713901 crossref_primary_10_2147_COPD_S308911 crossref_primary_10_1164_rccm_201703_0449OC crossref_primary_10_1183_23120541_00119_2017 crossref_primary_10_1007_s12325_021_01703_z |
| Cites_doi | 10.1378/chest.11-2231 10.1081/COPD-200050513 10.1183/09031936.04.00014304 10.1016/j.rmed.2012.12.014 10.1136/bmjopen-2013-003048 10.1016/j.pupt.2006.06.001 10.1378/chest.06-0702 10.1081/COPD-200053377 10.1016/j.rmed.2012.12.016 10.1016/j.rmed.2013.08.007 10.1183/09031936.00102509 10.1080/15412550802587943 10.1136/thx.2007.087213 10.1016/S2213-2600(14)70001-3 10.1183/09031936.00033213 10.1016/S2213-2600(12)70052-8 10.1186/1465-9921-15-78 10.1186/1465-9921-12-40 10.1183/09031936.00099306 10.1016/j.rmed.2011.09.002 10.1378/chest.11-0309 10.1016/S2213-2600(14)70065-7 10.7326/0003-4819-146-8-200704170-00152 10.1186/1465-9921-13-15 10.1016/j.rmed.2014.03.002 10.1081/COPD-200050666 10.1016/j.rmed.2013.06.001 10.1055/s-0030-1254072 10.1378/chest.13-1579 |
| ContentType | Journal Article |
| Copyright | 2015 The Authors The Authors Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Sep 2015 |
| Copyright_xml | – notice: 2015 The Authors – notice: The Authors – notice: Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Sep 2015 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7U9 ASE FPQ H94 K6X K9. M7N NAPCQ 7X8 |
| DOI | 10.1016/j.rmed.2015.06.006 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts British Nursing Index British Nursing Index (BNI) (1985 to Present) AIDS and Cancer Research Abstracts British Nursing Index ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-3064 |
| EndPage | 1163 |
| ExternalDocumentID | 3796319391 26117292 10_1016_j_rmed_2015_06_006 S0954611115300093 1_s2_0_S0954611115300093 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI CAG COF CS3 DU5 EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMK HMO HVGLF HZ~ IHE IXB J1W K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OI- OK1 OU. OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ RSU SAE SDF SDG SEL SES SEW SPCBC SSH SSZ SV3 T5K UHS UV1 WH7 WOW WUQ X7M Z5R ZGI ZXP ~G- 0SF 3V. 6I. 7RV 7X7 AACTN AAFTH ABVKL AFCTW AFKRA AFKWA AJOXV AMFUW BENPR M0T M2O NCXOZ RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX CITATION AGRNS CGR CUY CVF ECM EIF NPM 7U9 ASE FPQ H94 K6X K9. M7N NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c604t-737d6860136d6baabbffec0af329b5aae876d4b2cc0d2fbc406c437c93b1265a3 |
| IEDL.DBID | IXB |
| ISSN | 0954-6111 1532-3064 |
| IngestDate | Fri Sep 05 05:54:29 EDT 2025 Wed Aug 13 05:59:46 EDT 2025 Mon Jul 21 06:08:28 EDT 2025 Thu Apr 24 22:57:53 EDT 2025 Sun Aug 31 07:19:52 EDT 2025 Fri Feb 23 02:31:39 EST 2024 Sun Feb 23 10:19:34 EST 2025 Tue Aug 26 19:58:23 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | FF GOLD LS ITT PRO QoL UMEC ASE WM LABA HRQoL PBO Bronchodilation AE Long-acting muscarinic antagonist MedDRA CI Inhaled corticosteroid LAMA FVC VI SGRQ SAE CAT RI ICS FEV1 Long-acting beta2 agonist COPD umeclidinium forced vital capacity run-in vilanterol patient-reported outcome placebo fluticasone furoate St George's Respiratory Questionnaire adverse event health-related quality of life FEV 1 weighted mean least squares quality of life Global Initiative for Chronic Obstructive Lung Disease intent-to-treat Medical Dictionary for Regulatory Activities serious adverse event COPD Assessment Test all subjects enrolled Long-acting beta 2 agonist forced expiratory volume in one second confidence interval chronic obstructive pulmonary disease Long-acting beta agonist |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-nd/4.0 Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c604t-737d6860136d6baabbffec0af329b5aae876d4b2cc0d2fbc406c437c93b1265a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0954611115300093 |
| PMID | 26117292 |
| PQID | 1709240239 |
| PQPubID | 1216389 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1710652893 proquest_journals_1709240239 pubmed_primary_26117292 crossref_citationtrail_10_1016_j_rmed_2015_06_006 crossref_primary_10_1016_j_rmed_2015_06_006 elsevier_sciencedirect_doi_10_1016_j_rmed_2015_06_006 elsevier_clinicalkeyesjournals_1_s2_0_S0954611115300093 elsevier_clinicalkey_doi_10_1016_j_rmed_2015_06_006 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-09-01 |
| PublicationDateYYYYMMDD | 2015-09-01 |
| PublicationDate_xml | – month: 09 year: 2015 text: 2015-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | Respiratory medicine |
| PublicationTitleAlternate | Respir Med |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Aaron, Vandemheen, Fergusson (bib6) 2007; 146 Celli, Crater, Kilbride (bib23) 2014; 145 Hanania, Feldman, Zachgo (bib34) 2012; 142 Date last updated 2014. Date last accessed 22 December 2014. Cazzola, MacNee, Martinez (bib15) 2008; 31 Donohue, Maleki-Yazdi, Kilbride (bib22) 2013; 107 Jones (bib24) 2009; 6 Guarascio, Ray, Finch (bib2) 2013; 5 Singh, Brooks, Hagan (bib7) 2008; 63 Glaxo Group Limited (bib13) 2013 Westwood, Bourbeau, Jones (bib27) 2011; 12 Kon, Canavan, Jones (bib30) 2014; 2 Meguro, Barley, Spencer (bib19) 2007; 132 Trivedi, Richard, Mehta (bib21) 2014; 43 Cazzola, Ando, Santus (bib9) 2007; 20 Braido, Baiardini, Cazzola (bib32) 2013; 107 Jones, Harding, Berry (bib17) 2009; 34 Watkins, Wilcox, Tabberer (bib31) 2013; 3 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Vestbo, Vogelmeier, Small (bib11) 2014; 108 Celli, MacNee (bib3) 2004; 23 Decramer, Anzueto, Kerwin (bib20) 2014; 2 Jones (bib28) 2005; 2 Hanania, Crater, Morris (bib10) 2012; 106 Jones, Harding, Wiklund (bib18) 2012; 142 Kerwin, Scott-Wilson, Sanford (bib25) 2013; 107 World Medical Association (bib14) 2013 Vogelmeier, Bateman, Pallante (bib26) 2013; 1 GlaxoSmithKline (bib4) 2014 Chatterjee, Shah, D'Souza (bib8) 2012; 13 Mahler, Witek (bib29) 2005; 2 Donohue, Niewoehner, Brooks (bib35) 2014; 15 GlaxoSmithKline (bib12) 2014 Martinez, Boscia, Feldman (bib33) 2013; 107 Ohar, Donohue (bib5) 2010; 31 Donohue (bib16) 2005; 2 Ho, O'Mahony, Steward (bib36) 2001; 30 Singh (10.1016/j.rmed.2015.06.006_bib7) 2008; 63 Kerwin (10.1016/j.rmed.2015.06.006_bib25) 2013; 107 Donohue (10.1016/j.rmed.2015.06.006_bib35) 2014; 15 Ohar (10.1016/j.rmed.2015.06.006_bib5) 2010; 31 Trivedi (10.1016/j.rmed.2015.06.006_bib21) 2014; 43 Donohue (10.1016/j.rmed.2015.06.006_bib22) 2013; 107 Hanania (10.1016/j.rmed.2015.06.006_bib34) 2012; 142 Vogelmeier (10.1016/j.rmed.2015.06.006_bib26) 2013; 1 Ho (10.1016/j.rmed.2015.06.006_bib36) 2001; 30 Vestbo (10.1016/j.rmed.2015.06.006_bib11) 2014; 108 Kon (10.1016/j.rmed.2015.06.006_bib30) 2014; 2 Aaron (10.1016/j.rmed.2015.06.006_bib6) 2007; 146 Cazzola (10.1016/j.rmed.2015.06.006_bib9) 2007; 20 Donohue (10.1016/j.rmed.2015.06.006_bib16) 2005; 2 Jones (10.1016/j.rmed.2015.06.006_bib28) 2005; 2 Mahler (10.1016/j.rmed.2015.06.006_bib29) 2005; 2 Celli (10.1016/j.rmed.2015.06.006_bib3) 2004; 23 Westwood (10.1016/j.rmed.2015.06.006_bib27) 2011; 12 GlaxoSmithKline (10.1016/j.rmed.2015.06.006_bib12) 2014 Watkins (10.1016/j.rmed.2015.06.006_bib31) 2013; 3 Guarascio (10.1016/j.rmed.2015.06.006_bib2) 2013; 5 Jones (10.1016/j.rmed.2015.06.006_bib18) 2012; 142 Braido (10.1016/j.rmed.2015.06.006_bib32) 2013; 107 Chatterjee (10.1016/j.rmed.2015.06.006_bib8) 2012; 13 Hanania (10.1016/j.rmed.2015.06.006_bib10) 2012; 106 Martinez (10.1016/j.rmed.2015.06.006_bib33) 2013; 107 Cazzola (10.1016/j.rmed.2015.06.006_bib15) 2008; 31 Jones (10.1016/j.rmed.2015.06.006_bib24) 2009; 6 Decramer (10.1016/j.rmed.2015.06.006_bib20) 2014; 2 GlaxoSmithKline (10.1016/j.rmed.2015.06.006_bib4) 2014 10.1016/j.rmed.2015.06.006_bib1 Meguro (10.1016/j.rmed.2015.06.006_bib19) 2007; 132 Jones (10.1016/j.rmed.2015.06.006_bib17) 2009; 34 Glaxo Group Limited (10.1016/j.rmed.2015.06.006_bib13) 2013 World Medical Association (10.1016/j.rmed.2015.06.006_bib14) 2013 Celli (10.1016/j.rmed.2015.06.006_bib23) 2014; 145 Respir Med. 2015 Nov;109(11):1493 |
| References_xml | – volume: 108 start-page: 729 year: 2014 end-page: 736 ident: bib11 article-title: Understanding the GOLD 2011 strategy as applied to a real-world COPD population publication-title: Respir. Med. – volume: 107 start-page: 560 year: 2013 end-page: 569 ident: bib25 article-title: A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD publication-title: Respir. Med. – year: 2013 ident: bib14 article-title: WMA Declaration of Helsiniki - Ethical Principles for Medical Research Involving Human Subjects – volume: 15 start-page: 78 year: 2014 ident: bib35 article-title: Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study publication-title: Respir. Res. – year: 2014 ident: bib12 article-title: INCRUSE – volume: 5 start-page: 235 year: 2013 end-page: 245 ident: bib2 article-title: The clinical and economic burden of chronic obstructive pulmonary disease in the USA, Clinicoecon publication-title: Outcomes. Res. – volume: 2 start-page: 111 year: 2005 end-page: 124 ident: bib16 article-title: Minimal clinically important differences in COPD lung function publication-title: COPD – volume: 142 start-page: 119 year: 2012 end-page: 127 ident: bib34 article-title: The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial publication-title: Chest – volume: 107 start-page: 1538 year: 2013 end-page: 1546 ident: bib22 article-title: Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD publication-title: Respir. Med. – volume: 23 start-page: 932 year: 2004 end-page: 946 ident: bib3 article-title: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper publication-title: Eur. Respir. J. – volume: 31 start-page: 321 year: 2010 end-page: 333 ident: bib5 article-title: Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD publication-title: Semin. Respir. Crit. Care. Med. – volume: 2 start-page: 195 year: 2014 end-page: 203 ident: bib30 article-title: Minimum clinically important difference for the COPD Assessment Test: a prospective analysis publication-title: Lancet. Respir. Med. – volume: 30 start-page: 155 year: 2001 end-page: 159 ident: bib36 article-title: Dyspnoea and quality of life in older people at home, age publication-title: Ageing – volume: 20 start-page: 556 year: 2007 end-page: 561 ident: bib9 article-title: A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD publication-title: Pulm. Pharmacol. Ther. – volume: 13 start-page: 15 year: 2012 ident: bib8 article-title: Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease publication-title: Respir. Res. – volume: 2 start-page: 472 year: 2014 end-page: 486 ident: bib20 article-title: Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials publication-title: Lancet. Respir. Med. – year: 2014 ident: bib4 article-title: INCRUSE – volume: 1 start-page: 51 year: 2013 end-page: 60 ident: bib26 article-title: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study publication-title: Lancet. Respir. Med. – volume: 6 start-page: 59 year: 2009 end-page: 63 ident: bib24 article-title: Health status and the spiral of decline publication-title: COPD – volume: 107 start-page: 550 year: 2013 end-page: 559 ident: bib33 article-title: Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial publication-title: Respir. Med. – volume: 63 start-page: 592 year: 2008 end-page: 598 ident: bib7 article-title: Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD publication-title: Thorax – reference: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. – volume: 34 start-page: 648 year: 2009 end-page: 654 ident: bib17 article-title: Development and first validation of the COPD assessment test publication-title: Eur. Respir. J. – volume: 132 start-page: 456 year: 2007 end-page: 463 ident: bib19 article-title: Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire publication-title: Chest – volume: 146 start-page: 545 year: 2007 end-page: 555 ident: bib6 article-title: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial publication-title: Ann. Intern. Med. – volume: 142 start-page: 134 year: 2012 end-page: 140 ident: bib18 article-title: Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation publication-title: Chest – volume: 43 start-page: 72 year: 2014 end-page: 81 ident: bib21 article-title: Umeclidinium monotherapy in patients with COPD: a randomised, placebo-controlled study publication-title: Eur. Respir. J. – volume: 3 start-page: e003048 year: 2013 ident: bib31 article-title: Shortness of breath with daily activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease publication-title: BMJ. Open – volume: 107 start-page: 1465 year: 2013 end-page: 1480 ident: bib32 article-title: Long-acting bronchodilators improve health related quality of life in patients with COPD publication-title: Respir. Med. – volume: 12 start-page: 40 year: 2011 ident: bib27 article-title: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review publication-title: Respir. Res. – volume: 31 start-page: 416 year: 2008 end-page: 469 ident: bib15 article-title: Outcomes for COPD pharmacological trials: from lung function to biomarkers publication-title: Eur. Respir. J. – reference: . Date last updated 2014. Date last accessed 22 December 2014. – year: 2013 ident: bib13 article-title: RELVAR ELLIPTA – volume: 145 start-page: 981 year: 2014 end-page: 991 ident: bib23 article-title: Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study publication-title: Chest – volume: 106 start-page: 91 year: 2012 end-page: 101 ident: bib10 article-title: Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD publication-title: Respir. Med. – volume: 2 start-page: 99 year: 2005 end-page: 103 ident: bib29 article-title: The MCID of the transition dyspnea index is a total score of one unit publication-title: COPD – volume: 2 start-page: 75 year: 2005 end-page: 79 ident: bib28 article-title: St. George's Respiratory Questionnaire: MCID publication-title: COPD – volume: 142 start-page: 119 year: 2012 ident: 10.1016/j.rmed.2015.06.006_bib34 article-title: The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial publication-title: Chest doi: 10.1378/chest.11-2231 – year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib14 – volume: 2 start-page: 75 year: 2005 ident: 10.1016/j.rmed.2015.06.006_bib28 article-title: St. George's Respiratory Questionnaire: MCID publication-title: COPD doi: 10.1081/COPD-200050513 – volume: 23 start-page: 932 year: 2004 ident: 10.1016/j.rmed.2015.06.006_bib3 article-title: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper publication-title: Eur. Respir. J. doi: 10.1183/09031936.04.00014304 – volume: 107 start-page: 560 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib25 article-title: A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD publication-title: Respir. Med. doi: 10.1016/j.rmed.2012.12.014 – volume: 3 start-page: e003048 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib31 article-title: Shortness of breath with daily activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease publication-title: BMJ. Open doi: 10.1136/bmjopen-2013-003048 – volume: 20 start-page: 556 year: 2007 ident: 10.1016/j.rmed.2015.06.006_bib9 article-title: A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD publication-title: Pulm. Pharmacol. Ther. doi: 10.1016/j.pupt.2006.06.001 – volume: 132 start-page: 456 year: 2007 ident: 10.1016/j.rmed.2015.06.006_bib19 article-title: Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire publication-title: Chest doi: 10.1378/chest.06-0702 – volume: 2 start-page: 111 year: 2005 ident: 10.1016/j.rmed.2015.06.006_bib16 article-title: Minimal clinically important differences in COPD lung function publication-title: COPD doi: 10.1081/COPD-200053377 – volume: 107 start-page: 550 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib33 article-title: Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial publication-title: Respir. Med. doi: 10.1016/j.rmed.2012.12.016 – volume: 107 start-page: 1465 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib32 article-title: Long-acting bronchodilators improve health related quality of life in patients with COPD publication-title: Respir. Med. doi: 10.1016/j.rmed.2013.08.007 – volume: 30 start-page: 155 year: 2001 ident: 10.1016/j.rmed.2015.06.006_bib36 article-title: Dyspnoea and quality of life in older people at home, age publication-title: Ageing – volume: 34 start-page: 648 year: 2009 ident: 10.1016/j.rmed.2015.06.006_bib17 article-title: Development and first validation of the COPD assessment test publication-title: Eur. Respir. J. doi: 10.1183/09031936.00102509 – volume: 6 start-page: 59 year: 2009 ident: 10.1016/j.rmed.2015.06.006_bib24 article-title: Health status and the spiral of decline publication-title: COPD doi: 10.1080/15412550802587943 – volume: 63 start-page: 592 year: 2008 ident: 10.1016/j.rmed.2015.06.006_bib7 article-title: Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD publication-title: Thorax doi: 10.1136/thx.2007.087213 – volume: 2 start-page: 195 year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib30 article-title: Minimum clinically important difference for the COPD Assessment Test: a prospective analysis publication-title: Lancet. Respir. Med. doi: 10.1016/S2213-2600(14)70001-3 – year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib13 – volume: 43 start-page: 72 year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib21 article-title: Umeclidinium monotherapy in patients with COPD: a randomised, placebo-controlled study publication-title: Eur. Respir. J. doi: 10.1183/09031936.00033213 – volume: 1 start-page: 51 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib26 article-title: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study publication-title: Lancet. Respir. Med. doi: 10.1016/S2213-2600(12)70052-8 – volume: 15 start-page: 78 year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib35 article-title: Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study publication-title: Respir. Res. doi: 10.1186/1465-9921-15-78 – volume: 12 start-page: 40 year: 2011 ident: 10.1016/j.rmed.2015.06.006_bib27 article-title: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review publication-title: Respir. Res. doi: 10.1186/1465-9921-12-40 – volume: 31 start-page: 416 year: 2008 ident: 10.1016/j.rmed.2015.06.006_bib15 article-title: Outcomes for COPD pharmacological trials: from lung function to biomarkers publication-title: Eur. Respir. J. doi: 10.1183/09031936.00099306 – volume: 106 start-page: 91 year: 2012 ident: 10.1016/j.rmed.2015.06.006_bib10 article-title: Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD publication-title: Respir. Med. doi: 10.1016/j.rmed.2011.09.002 – volume: 142 start-page: 134 year: 2012 ident: 10.1016/j.rmed.2015.06.006_bib18 article-title: Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation publication-title: Chest doi: 10.1378/chest.11-0309 – volume: 2 start-page: 472 year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib20 article-title: Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials publication-title: Lancet. Respir. Med. doi: 10.1016/S2213-2600(14)70065-7 – volume: 146 start-page: 545 year: 2007 ident: 10.1016/j.rmed.2015.06.006_bib6 article-title: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-146-8-200704170-00152 – volume: 5 start-page: 235 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib2 article-title: The clinical and economic burden of chronic obstructive pulmonary disease in the USA, Clinicoecon publication-title: Outcomes. Res. – ident: 10.1016/j.rmed.2015.06.006_bib1 – volume: 13 start-page: 15 year: 2012 ident: 10.1016/j.rmed.2015.06.006_bib8 article-title: Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease publication-title: Respir. Res. doi: 10.1186/1465-9921-13-15 – volume: 108 start-page: 729 year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib11 article-title: Understanding the GOLD 2011 strategy as applied to a real-world COPD population publication-title: Respir. Med. doi: 10.1016/j.rmed.2014.03.002 – year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib12 – year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib4 – volume: 2 start-page: 99 year: 2005 ident: 10.1016/j.rmed.2015.06.006_bib29 article-title: The MCID of the transition dyspnea index is a total score of one unit publication-title: COPD doi: 10.1081/COPD-200050666 – volume: 107 start-page: 1538 year: 2013 ident: 10.1016/j.rmed.2015.06.006_bib22 article-title: Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD publication-title: Respir. Med. doi: 10.1016/j.rmed.2013.06.001 – volume: 31 start-page: 321 year: 2010 ident: 10.1016/j.rmed.2015.06.006_bib5 article-title: Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD publication-title: Semin. Respir. Crit. Care. Med. doi: 10.1055/s-0030-1254072 – volume: 145 start-page: 981 year: 2014 ident: 10.1016/j.rmed.2015.06.006_bib23 article-title: Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study publication-title: Chest doi: 10.1378/chest.13-1579 – reference: - Respir Med. 2015 Nov;109(11):1493 |
| SSID | ssj0009440 |
| Score | 2.4015064 |
| Snippet | The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone... Abstract Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added... The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone... Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1155 |
| SubjectTerms | Adrenergic beta-2 Receptor Agonists - adverse effects Adrenergic beta-2 Receptor Agonists - therapeutic use Aged Androstadienes - adverse effects Androstadienes - therapeutic use Benzyl Alcohols - adverse effects Benzyl Alcohols - therapeutic use Bronchodilation Chlorobenzenes - adverse effects Chlorobenzenes - therapeutic use Chronic obstructive pulmonary disease Dose-Response Relationship, Drug Double-Blind Method Drug Combinations Drug dosages Drug Therapy, Combination Female Forced Expiratory Volume - drug effects Glucocorticoids - adverse effects Glucocorticoids - therapeutic use Humans Inhaled corticosteroid Long-acting beta2 agonist Long-acting muscarinic antagonist Male Middle Aged Mortality Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - adverse effects Muscarinic Antagonists - therapeutic use Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Pulmonary/Respiratory Quality of Life Quinuclidines - administration & dosage Quinuclidines - adverse effects Quinuclidines - therapeutic use Respiratory diseases Studies Vital Capacity - drug effects |
| Title | Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0954611115300093 https://www.clinicalkey.es/playcontent/1-s2.0-S0954611115300093 https://dx.doi.org/10.1016/j.rmed.2015.06.006 https://www.ncbi.nlm.nih.gov/pubmed/26117292 https://www.proquest.com/docview/1709240239 https://www.proquest.com/docview/1710652893 |
| Volume | 109 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1532-3064 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1532-3064 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Freedom Collection Journals customDbUrl: eissn: 1532-3064 dateEnd: 20230929 omitProxy: true ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection Journals customDbUrl: eissn: 1532-3064 dateEnd: 20230929 omitProxy: true ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Open Access Journals (Elsevier) customDbUrl: eissn: 1532-3064 dateEnd: 20230929 omitProxy: true ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: IXB dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1532-3064 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: AKRWK dateStart: 19890501 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkRAXxJuFsjISNxR2kzhOwq1UrRZQewAq7c3yK1KqNFltkqLtoX-Dv8uM42yFKEXimMTWWPZ45pt45jMhb5HUyqR5HhQFtwELpQoycFOBYrlJZV4YxbDA-fiEL07Z52Wy3CEHYy0MplV62z_YdGet_ZuZn83Zqixn3wAcMI47PoldYA52OGapK-Jbfrwm3mWuKBIbB9jaF84MOV5r8DiY3pU4Dk-89ehm5_Q38Omc0NFD8sCjR7o_DPAR2bH1Y3Lv2J-PPyE_D5ERQuoNlbWhrSxst6FNQcEA6aoEN1X25xRtjaFdQ4vK_ckGxG1p0a8bgJ2zi7Jyc91UtKypHqhzaaM8z-yFpau-AtWV6w31hzsf6Ffb9lXXoqTuR0PB_ZnmvLwEKe2QpviUnB4dfj9YBP7qhUDzOeuCNE4NzzgSuhmupFQKs0vmsoijXCVSWjCihqlI67mJCqUBFmgWpzqPVRjxRMbPyG4No39BKDeAkADHpIpJlmeZypSOEm1CBaEiwJEJCcc5F9rzkuP1GJUYE9DOBK6TwHUSLguPT8i7bZ_VwMpxa-t4XEox1puChRTgNG7tld7Uy7Z-k7ciFG0k5uIPRZyQZNvzN13-p8S9Uc_EtZB0nuMJWJxPyJvtZ7ABeLAja9v02AYC-wRCZxD9fNDP7bRAhAwYNY9e_uegXpH7-DSk1e2RXdA2-xpwWKem5M77q3BK7u5_-rI4mbpt9wuncDUc |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbKVgIuiDcLBYzEDUWbh_Mwt6pqtaXdPUAr9Wb5FSlVmqw2SdHyR_i7zCTOVohSJK4bj8ayxzPfrGc-E_IRSa1MyrmX54n1WCCVl0GY8hTjJpU8N4phg_NimczP2ZeL-GKHHIy9MFhW6Xz_4NN7b-1-mbnVnK2KYvYNwAFL8MTHUZ-Y3yO7LAafPCG7-8cn8-UN9y7r-yJxvIcCrndmKPNaQ9DBCq-4p_HEh49uj09_w599HDp6TB45AEn3hzk-ITu2ekruL9wV-TPy8xBJIaTeUFkZ2sjcthta5xR8kC4LiFRFd0XR3Rja1jQv-z-zAXRbmnfrGpDn7Loo--WuS1pUVA_subRWjmr22tJVV4L1yvWGuvudz_SrbbqybVBT-72mEAFNfVX8AC3NUKn4nJwfHZ4dzD33-oKnE5-1XhqlJskS5HQziZJSKSww8WUehVzFUlrwo4apUGvfhLnSgAw0i1LNIxWESSyjF2RSwexfEZoYAEkAZVLFJONZpjKlw1ibQEG2CIhkSoJxzYV21OT4QkYpxhq0S4H7JHCfRF-Il0zJp63MaiDmuHN0NG6lGFtOwUkKiBt3SqW3SdnGnfNGBKIJhS_-sMUpibeSv5nzPzXujXYmbpSkPsdLsIhPyYftZ3ADeLcjK1t3OAZy-xiyZ1D9crDP7bJAkgwwlYev_3NS78mD-dniVJweL0_ekIf4Zaiy2yMTsDz7FmBZq965Y_cLtrA2vw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+umeclidinium+added+to+fluticasone+furoate%2Fvilanterol+in+chronic+obstructive+pulmonary+disease%3A+Results+of+two+randomized+studies&rft.jtitle=Respiratory+medicine&rft.au=Siler%2C+Thomas+M&rft.au=Kerwin%2C+Edward&rft.au=Sousa%2C+Ana+R&rft.au=Donald%2C+Alison&rft.date=2015-09-01&rft.pub=Elsevier+Limited&rft.issn=0954-6111&rft.eissn=1532-3064&rft.volume=109&rft.issue=9&rft.spage=1155&rft_id=info:doi/10.1016%2Fj.rmed.2015.06.006&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3796319391 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09546111%2FS0954611115X00096%2Fcov150h.gif |